Popescu Cristina, Aramă Victoria
“Matei Bals” National Institute of Infectious Diseases, “Carol Davila” University of Medicine and Pharmacy
Abstract
Pegylated interferon and ribavirin are mandatory in the treatment of HCV hepatitis. An early recognition of side effects related to the antiviral therapy can prevent the discontinuation of treatment and can improve the eradication of HCV infection. Hematologic side effects related to pegylated interferon and ribavirin therapy are the most studied; on the other hand it is difficult to make a correlation between a rarely reported side effect and the medication. That’s why it is important to report and to recognize all these side effects in order to avoid life-threatening. This review analyses non-hematologic side effects correlated with antiviral therapy for HCV hepatitis.